Lannett shares should be bought on weakness, says Oppenheimer After Lannett reduced its Q4 guidance but provided higher than expected FY15 revenue guidance based on price increases it has implemented, Oppenheimer believes that investors should be pleased with the overall guidance. The firm keeps a $49 price target and Outperform rating on the stock.
Senate Health, Education, Labor & Pensions Committee to hold a hearing The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link